Clinical Study On Treating Chronic Obstructive Pulmonary Disease Stable Stage(Qi Deficiency And Blood Stasis Syndrome) With The Yiqi Huoxue Decoction

Objective: By observing the clinical efficacy of Yiqi Huoxue Decoc tion combined with long-acting bronchodilators and long-acting bronchodilators alone in patients with chronic obstructive pulmonary disease with qi deficiency and blood stasis during the stable period,explore two methods of treatment for patients with pulmonary function,clinical Changes in symptoms,hemorheology,acute exacerbations,quality of life assessment,and dyspnea symptoms.To summarize the mechanism of Yiqi Huoxue Decoction combined with long-acting bronchodilators in the treatment of patients with stable chronic obstructive pulmonary disease,provide more methods for clinical treatment of the disease,and provide more clinical treatment for this disease with integrated traditional Chinese and western medicine Evidence support.Method: 60 patients with chronic obstructive pulmonary disease with stable qi deficiency and blood stasis syndrome were randomly divided into treatment group and control group using random number table method,30 patients in each group.The control group used long-acting bronchodilator(including British production of Glaxo Smith Kline).The combination of salom etrixone powder inhaler 50ug/250 ug and Chia Taiqing Pharmac eutical’s Tiotropium Bromide aerosol 18ug)was used.The treatment group was treated with long-acting bronchodilators(control group)and supplemented with Yiqi Huoxue Syndrome.After 12 weeks of continuous treatment,the basic information of 60 patients was extracted.The course of disease,severity of illness,pulmonary function,hemorheology indexes,quality of life scores,dyspnea,and symptom scores of TCM were analyzed before and after treatment in both groups.Data,and follow-up records the number of acute exacerbations within 1 year after treatment.The data in this study were statistically analyzed using statistical software SPSS21.0.Results: 1.Analysis of the effect of TCM syndromes:After treatment in the two groups,the total effective rate was 93% in the treatment group and 83% in the control group.The number of clinical control,effective,effective,and ineffective treatment groups was 8,13,6,and 2 respectively.The control group was 5,7,13,and 5.The total efficacy of the two groups was statistically significant(P<0.05).The treatment group was superior to the control group.2.Evaluation of pulmonary ventilation function:There was no significant difference in the predicted FEV1/FVC and FEV1% between the two groups before treatment(P>0.05),and they were comparable;before and after treatment in the two groups,FEV1/FVC and FEV1% in both groups were evaluated.The predicted value was higher than before,and the difference was statistically significant(P<0.05);the predicted FEV1/FV Cand FEV1% of the two groups had statistically significant difference(P<0.05)after treatment,and the treatment group’s The degree of improvement was better than that of the control group;after treatment,there was a statistically significant difference in the number of stable lung functionbe tween the two groups(P<0.05).The number of stable lung function in the treatment group was more than that in the controlgroup.3.Comparison of the number of acute exacerbations:There was a statistically significant difference between the two groups in the number of acute exacerbations followed up for one year(P<0.05),and the number of acute exacerbations in the treatment group was significantly lower than that in thecontrol group.4.Comparison of TCM symptom scores:There was no significant difference between the two groups before the treatment of 9 symptoms including cough,expectoration,wheezing,chest tightness and belching(P>0.05).The symptoms were comparab le between the two groups.Before and after the intragroup comparison,the difference was statistically significant(P<0.05).The difference between the two groups after symptomat ic treatment was statistically significant(P<0.05).The symptom scores in the treatment group decreased more signific antly than the control group.5.Comparison of hemorheology indexes:There was no significant difference between the two groups in the high-cut,low-shear viscosity and blood viscosity of the whole blood before treatment(P>0.05).The treatment group was compared b efore and after treatment.The difference was statistically significant(P<0.05).There was no significant difference between the two groups before and after treatment in the control group(P>0.05).There was a statistically significant difference between the two groups after treatment(P<0.05).The treatment group was better than the control group.group.6.Improvement in the severity of dyspnea: There were no statistically significant differences between the two groups in the distribution of mMRC before treatment(P>0.05).The difference was statistically significant between the two groups before and after treatment.P<0.05),although the control group also improved,but the difference was not statistically significant(P>0.05);m MRC grade distribution in the two groups after treatment,the difference was statistically significant(P<0.05),the treatment group breathe The difficulty improvement is better than that of the control gro up.7.Improvement of quality of life:There was no difference in the CAT score between the two groups before treatment(P>0.05),and there was comparability;the difference between the two groups before and after treatment was statistically significant(P<0.05);After the comparison,the difference was statistically significant(P<0.05),and the CAT score of the treatment group was more improved than that of the control group.Conclusion: Combination of Yiqi Huoxue Decoction and Western Medicine Long-acting Bronchodilator for COPD patients with qi deficiency and blood stasis during stable period can improve pulmonary function,delay the decline of lung function,relieve clinical symptoms,improve hemorheological indexes,and promote blood in patients with stable COPD.Circulation,reduce the number of acute attacks,improve the symptoms of dyspnea,improve the quality of life of patients,and increase thecon fidence of patients in resisting evils.It has been proved through research that Yiqi Huoxue decoction combined withlon g-acting bronchodilators is more effective than single-use inhaled long-acting bronchodilators in the treatment of pat ients with stable COPD,indicating that Chinese and Western medicine treatment is more efficient and capable of differe ntiating and treating different patients.The clinical efficacy is reliable.